LFA3 variants and compositions and uses thereof
By developing LFA3-Fc fusion polypeptide molecules to regulate the interaction between CD2 and LFA3, the problem of difficulty in effectively regulating CD2-LFA3 interaction in the prior art is solved, and effective treatment of autoimmune diseases is achieved.
JP2025060698APending Publication Date: 2025-04-10PFIZER INC +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024218928
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2024-12-13
- Publication Date
- 2025-04-10
Smart Images
Figure 2025060698000001_ABST
Abstract
To provide LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules.SOLUTION: The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.SELECTED DRAWING: Figure 14A
Need to check novelty before this filing date? Find Prior Art